Sharechat Logo

Pacific Edge shares drop 9.4% as slow sales progress bring cash burn in focus

Tuesday 29th May 2018

Text too small?

Pacific Edge shares fell 9.4 percent after the company stayed in the red and said commercial deals in the US were taking longer than expected, raising questions about whether its cash reserves are deep enough. 

"Things seem to be moving quite slowly for the company, slower than what management thought," said Grant Williamson, director at Christchurch-based Hamilton Hindin Greene. 

Pacific Edge, which has a suite of four Cxbladder cancer diagnostics tests, had $16.2 million in cash and cash equivalents at March 31, including proceeds from the capital raise in November 2017. Pacific Edge raised $21.3 million in a deeply discounted rights issue, which it said would fund its goal to break even in the 2019 financial year. Its operational cash outflow widened to $18.1 million from $17.8 million. 

"Cash is going to be a concern in several months time ... they need to generate more sales in order to reduce their cash burn which unfortunately, because of these slow negotiations, hasn't eventuated at this stage." 

The shares dropped 3 cents to 29 cents and have fallen 18 percent so far this year. 

The Dunedin-based company reported a loss of $19.7 million in the year to March 31, or 4.5 cents per share, versus a loss of $22.6 million in the prior year, or 5.7 cents per share, after the prior year was restated in line with the NZ IFRS 15 revenue accounting standards. 

Pacific Edge said while it has progressed commercial negotiations with targeted large-scale healthcare organisations in the US over the past 12 months, including Kaiser Permanente and the Centers for Medicare and Medicaid, both are taking longer than expected to complete.

"Pacific Edge has little to no control over the decision making processes and timings of these large organisations," it said. 

"The multi-billion dollar US healthcare market remains our most significant opportunity and we are seeking to position Cxbladder as the preferred diagnostic test of choice for physicians in a market that offers more than 5 million potential test opportunities per annum," said chair Chris Gallaher. 


  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Take care to avoid "unnecessary" cost in electrifying economy - Vivid
Is this the calm before a storm of credit card thrashing?
Shrinking meat and dairy product manufacturing weighs on growth outlook
Jon Macdonald to stay on as Trade Me boss through takeover tussle
Shareholders’ Association wants Finzsoft to come clean
A2 rings in more executive changes under new CEO Hrdlicka
NZ dollar dips as China-US trade tensions cast pall over global markets
No end in sight to global market turmoil
MARKET CLOSE: NZ shares rally on speculation of flat US rate track; Spark gains
Fed's wait-and-see signal keeps NZ dollar steady for the week

IRG See IRG research reports